Titan Pharmaceuticals Secures $600,000 Investment to Fuel Growth
New York, NY – June 27, 2025 – Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the triumphant completion of a private placement, securing $600,000 in funding thru the issuance of Series C Convertible Preferred Stock. The investment comes from blue Harbour Asset Management L.L.C-FZ, a key player in the financial markets.
Details of the Investment
The transaction involved the sale of 60,000 shares of the newly designated Preferred Stock to Blue Harbour at a total price of $600,000. Each share carries a conversion price of $3.40, offering a potential pathway for future equity conversion. This influx of capital is anticipated to bolster Titan’s ongoing research and development initiatives and support the commercialization of its pharmaceutical pipeline.
Safeguarding Shareholder Interests
A key component of the agreement is a beneficial ownership conversion feature embedded within the Certificate of Designations for the Preferred Stock. This “blocker” provision is designed to prevent Blue Harbour from exceeding specific ownership thresholds – either the maximum permitted by Nasdaq regulations or 19.99% of Titan’s outstanding common stock – without first obtaining approval from existing shareholders. This measure ensures that current investors retain a significant voice in the company’s direction.
regulatory Compliance and Future registration
The private placement was conducted under Regulation S and did not involve a public offering,meaning the shares have not yet been registered with the Securities and Exchange Commission (SEC) under the Securities Act of 1933. Though, Titan and Blue Harbour have simultaneously entered into a Registration Rights Agreement. This agreement obligates Titan to pursue registration rights for the shares under certain predefined conditions, perhaps allowing for future public trading.Investors can find extensive details regarding this agreement in a recently filed 8-K report with the SEC.
Financial Advisory Support
ARC Group Ltd. played a crucial role in facilitating this transaction, serving as the sole financial advisor to Titan Pharmaceuticals throughout the private placement process. Their expertise was instrumental in navigating the complexities of the deal and securing favorable terms for the company.
Looking Ahead: Significant Considerations
This investment represents a significant step forward for Titan Pharmaceuticals. Though, investors should be aware that the pharmaceutical industry is inherently subject to various risks. These include challenges in securing regulatory approvals, the lengthy and costly nature of drug development, potential intellectual property disputes, and the ever-present need for additional capital.
Disclaimer: This press release contains forward-looking statements, which are subject to risks and uncertainties that could materially impact Titan Pharmaceuticals’ business, operating results, financial condition, and stock price. These statements are not guarantees of future performance and should be considered in light of the factors outlined in the company’s filings with the SEC. Titan Pharmaceuticals disclaims any obligation to update or revise these forward-looking statements, except as required by law.